Prospera-powered monitoring for any transplant patient

Who is being missed?

Every patient has a unique and complex set of risks for transplant rejection. Surveillance testing with Prospera can have a positive impact for any patient risk profile.

Regularly scheduled testing with Prospera identifies out-of-baseline trends that may indicate larger transplant issues, enabling physicians and patients to quickly tailor healthcare with the most current data. And, Prospera’s simple blood draw can be run along with other labs, limiting patient inconvenience while maximizing peace of mind.

Let’s check out how Prospera provides different benefits based on the varying complexities of each patient.

Key Clinical Factors to Consider when Assessing for Transplant Rejection

DONOR-SPECIFIC ALLOANTBODY (DSA) DETECTED	HISTORY OF REJECTION	NON-ADHERENCE OF ANTI-REJECTION MEDICATION	HIGH CALCULATED (CPRA)	DELAYED GRAFT FUNCTION (DGF) OCCURENCE	DECREASED IMMUNE SUPPRESSION DUE TO INFECTION AND/OR ADVERSE EFFECTS	GEOGRAPHIC DISTANCE OR ACCESS TO TRANSPLANT CENTER

Meet our Prospera patients

Meet Mary, 31, African American

Through Mary’s case, learn how Prospera can identify the need for a biopsy and lead to a change in treatment.

View Mary’s profile

Meet John, 37, Hispanic

Through John’s case, learn how Prospera can help limit unnecessary biopsies.

View John’s profile

Meet Mike, 61, Caucasian

Through Mike’s case, learn how Prospera can help identify subclinical rejection and allow for earlier treatment.

View Mike’s profile

Meet Mary

PATIENT	CLINICAL NOTES	KEY TAKEAWAY
	End stage renal disease(ESRD) due to Goodpasture syndrome Second kidney transplant in 2015 when she was 25; her calculated panel reactive antibody (cPRA) at the time was 98% DSAs have been detected Lives far from the transplant center and often has trouble finding transportation to her appointments	Prospera surveillance testing allowed Mary’s doctor to closely track drastic fluctuations from the baseline result, which served as an early warning that something more problematic may soon occur. The subsequent results led to a confirmatory biopsy and a modification in treatment — which ultimately may have saved the graft in this complex patient. Download Mary’s case study to learn more details about her clinical results. Download Mary’s case study

PATIENT

CLINICAL NOTES

KEY TAKEAWAY

End stage renal disease(ESRD) due to Goodpasture syndrome
Second kidney transplant in 2015 when she was 25; her calculated panel reactive antibody (cPRA) at the time was 98%
DSAs have been detected
Lives far from the transplant center and often has trouble finding transportation to her appointments

Prospera surveillance testing allowed Mary’s doctor to closely track drastic fluctuations from the baseline result, which served as an early warning that something more problematic may soon occur. The subsequent results led to a confirmatory biopsy and a modification in treatment — which ultimately may have saved the graft in this complex patient.

Download Mary’s case study to learn more details about her clinical results.

Download Mary’s case study

Meet John

PATIENT	CLINICAL NOTES	KEY TAKEAWAY
	Glomerulonephritis(GN) since early teens caused End-stage renal disease (ESRD) Received first transplant from mother (one haplotype match related donor) with good initial function Multiple rejections and recurrent GN caused graft loss after two years October 2016 — biopsy indicated antibody-mediated acute rejection(ABMR), with serum creatinine (sCR) of 1.8 mg/DL and positive for DSA. Treated with IVIG plasmapheresis and rituximab. June 2017 — biopsy showed tubulitis with tubular atrophy and indicated Banf 1A T-cell mediated rejection (TCMR). Treated with pulse steroids. February 2020 — developed cytomegalovirus (CMV) and DSAs remained detectable. His mycophenolate mofetil(MMF) was reduced from 1000 mg twice daily to 500mg twice daily.	Prospera surveillance testing allowed John’s doctor to closely track drastic fluctuations from the baseline result, which served as reassurance even though the Cr levels were rising. After a potentially unnecessary biopsy in January 2021, the physician determined the future biopsies may be avoidable when Prospera results are available to supplement fluctuating Cr results due to Prospera’s strong negative predict value. Download John’s case study to learn more details about her clinical results. Download John’s case study View recent scientific poster

PATIENT

CLINICAL NOTES

KEY TAKEAWAY

Glomerulonephritis(GN) since early teens caused End-stage renal disease (ESRD)
Received first transplant from mother (one haplotype match related donor) with good initial function
Multiple rejections and recurrent GN caused graft loss after two years
October 2016 — biopsy indicated antibody-mediated acute rejection(ABMR), with serum creatinine (sCR) of 1.8 mg/DL and positive for DSA. Treated with IVIG plasmapheresis and rituximab.
June 2017 — biopsy showed tubulitis with tubular atrophy and indicated Banf 1A T-cell mediated rejection (TCMR). Treated with pulse steroids.
February 2020 — developed cytomegalovirus (CMV) and DSAs remained detectable. His mycophenolate mofetil(MMF) was reduced from 1000 mg twice daily to 500mg twice daily.

Prospera surveillance testing allowed John’s doctor to closely track drastic fluctuations from the baseline result, which served as reassurance even though the Cr levels were rising. After a potentially unnecessary biopsy in January 2021, the physician determined the future biopsies may be avoidable when Prospera results are available to supplement fluctuating Cr results due to Prospera’s strong negative predict value.

Download John’s case study to learn more details about her clinical results.

Download John’s case study

View recent scientific poster

Meet Mike

PATIENT	CLINICAL NOTES	KEY TAKEAWAY
	End stage Renal disease (ESRD) due to diabetes associated with hypertension, obesity (BMI 33) and non-obstructive coronary artery disease(CAD) cPRA was 98% No DSA detected pre-transplant Transplant: July 2020 from a deceased donor renal transplant(DDRT) with kidney donor profile index(KDPI) of 70% Transplant was complicated by DGF, hemodialysis on post-operative days # 1,3,8,11,14,18. Transplant was complicated by DGF, hemodialysis on post operative days # 1, 3, 8, 11, 14, 18 On post-operative day #17, due to prolonged DGF, biopsy was negative for rejection, but acute tubular injury with isometric vacuolization(possible calcineurin inhibitor (CNI) toxicity), moderate arteriosclerosis (donor derived), C4d negative, interstitial fibrosis and tubular atrophy (IFTA) 5% On post-operative day #18, Prospera result was 0.29% Tacrolimus dose reduced after biopsy (trough was 11.5 prior to biopsy)	Monitoring kidney transplant recipients with Prospera may help identify subclinical rejection and allow for earlier treatment instead of relying on serum creatinine alone. Download Mike’s case study to learn more details about his clinical results. Download Mike’s case study

PATIENT

CLINICAL NOTES

KEY TAKEAWAY

End stage Renal disease (ESRD) due to diabetes associated with hypertension, obesity (BMI 33) and non-obstructive coronary artery disease(CAD)
cPRA was 98%
No DSA detected pre-transplant
Transplant: July 2020 from a deceased donor renal transplant(DDRT) with kidney donor profile index(KDPI) of 70%
Transplant was complicated by DGF, hemodialysis on post-operative days # 1,3,8,11,14,18. Transplant was complicated by DGF, hemodialysis on post operative days # 1, 3, 8, 11, 14, 18
On post-operative day #17, due to prolonged DGF, biopsy was negative for rejection, but acute tubular injury with isometric vacuolization(possible calcineurin inhibitor (CNI) toxicity), moderate arteriosclerosis (donor derived), C4d negative, interstitial fibrosis and tubular atrophy (IFTA) 5%
On post-operative day #18, Prospera result was 0.29%
Tacrolimus dose reduced after biopsy (trough was 11.5 prior to biopsy)

Monitoring kidney transplant recipients with Prospera may help identify subclinical rejection and allow for earlier treatment instead of relying on serum creatinine alone.

Download Mike’s case study to learn more details about his clinical results.

Download Mike’s case study